Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 2, 2006 - Issue 1
Submit an article Journal homepage
333
Views
37
CrossRef citations to date
0
Altmetric
Review

Molecular mechanisms for drug interactions with hERG that cause long QT syndrome

Phillip J Stansfeld PhD Student in Bioinformatics, University of Leicester, Department of Cell Physiology & Pharmacology, Medical Sciences Building, University Road, Leicester, LE1 9HN, UK. [email protected]
,
Michael J Sutcliffe Professor at the Manchester Interdisciplinary Biocentre, University of Manchester, School of Chemical Engineering and Analytical Science (CEAS), The Mill, PO Box 88, Manchester, M60 1QD, UK
&
John S Mitcheson Lecturer in Physiology and Pharmacology, University of Leicester, Department of Cell Physiology & Pharmacology, Medical Sciences Building, University Road, Leicester, LE1 9HN, UK
Pages 81-94 | Published online: 01 Feb 2006

Bibliography

  • ROY M, DUMAINE R, BROWN AM: HERG, a primary human ventricular target of the nonsedating antihistamine terfenadine. Circulation (1996) 94(4):817-823.
  • RAMPE D, ROY ML, DENNIS A, BROWN AM: A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG. FEBS Lett. (1997) 417(1):28-32.
  • DOYLE DA, MORAIS CABRAL J, PFUETZNER RA etal.: The structure of the potassium channel: molecular basis of K+ conduction and selectivity. Science (1998) 280(5360):69-77.
  • ZHOU Y, MORAIS-CABRAL JH, KAUFMAN A, MACKINNON R: Chemistry of ion coordination and hydration revealed by a K+ channel-Fab complex at 2.0 A resolution. Nature (2001) 414(6859):43-48.
  • JIANG Y, LEE A, CHEN J etal.: The open pore conformation of potassium channels. Nature (2002) 417(6888):523-526.
  • MORAIS CABRAL JH, LEE A, COHENSL etal.: Crystal structure and functional analysis of the HERG potassium channel N terminus: a eukaryotic PAS domain. Cell (1998) 95(5):649-655.
  • ZAGOTTA WN, OLIVIER NB, BLACKKD etal.: Structural basis for modulation and agonist specificity of HCN pacemaker channels. Nature (2003) 425(6954):200-205.
  • CLAYTON GM, SILVERMAN WR, HEGINBOTHAM L, MORAIS-CABRALJH: Structural basis of ligand activation in a cyclic nucleotide regulated potassium channel. Cell (2004) 119(5):615-627.
  • LIU J, ZHANG M, JIANG M, TSENGGN: Structural and functional role of the extracellular s5-p linker in the HERG potassium channel. J. Gen. Physiol. (2002) 120(5):723-737.
  • TORRES AM, BANSAL PS, SUNDE M etal.: Structure of the HERG K+ channel S5P extracellular linker: role of an amphipathic alpha-helix in C-type inactivation. J. Biol. Chem. (2003) 278(43):42136-42148.
  • PARDO-LOPEZ L, ZHANG M, LIU J etal.: Mapping the binding site of a human ether-a-go-go-related gene-specific peptide toxin (ErgTx) to the channels outer vestibule. J. Biol. Chem. (2002) 277(19):16403-16411.
  • MORAIS-CABRAL JH, ZHOU Y, MACKINNON R: Energetic optimization of ion conduction rate by the K+ selectivity filter. Nature (2001) 414(6859):37-42.
  • BERNECHE S, ROUX B: Energetics of ion conduction through the K+ channel. Nature (2001) 414(6859):73-77.
  • SHRIVASTAVA IH, TIELEMAN DP, BIGGIN PC, SANSOM MS: K(+) versus Na(+) ions in a K channel selectivity filter: a simulation study. Biophys. J. (2002) 83(2):633-645.
  • ZHOU Y, MACKINNON R: Ion binding affinity in the cavity of the KcsA potassium channel. Biochemistry (2004) 43(17):4978-4982.
  • JIANG Y, LEE A, CHEN J etal.: X-ray structure of a voltage-dependent K+ channel. Nature (2003) 423(6935):33-41.
  • YANG T, RODEN DM: Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence. Circulation (1996) 93(3):407-411.
  • WANG S, MORALES MJ, LIU S, STRAUSS HC, RASMUSSON RL: Modulation of HERG affinity for E-4031 by [K+]o and C-type inactivation. FEBS Lett. (1997) 417(1):43-47.
  • MITCHESON JS, CHEN J, LIN M, CULBERSON C, SANGUINETTI MC: A structural basis for drug-induced long QT syndrome. Proc. Natl. Acad. Sci.USA (2000) 97(22):12329-12333.
  • MITCHESON JS, CHEN J, SANGUINETTI MC: Trapping of a methanesulfonanilide by closure of the HERG potassium channel activation gate. J. Gen. Physiol. (2000) 115(3):229-240.
  • LONG SB, CAMPBELL EB, MACKINNON R: Crystal structure of a mammalian voltage-dependent Shaker family K+ channel. Science (2005) 309(5736):897-903.
  • DEL CAMINO D, HOLMGREN M, LIUY, YELLEN G: Blocker protection in the pore of a voltage-gated K+ channel and its structural implications. Nature (2000) 403(6767):321-325.
  • KAMIYA K, MITCHESON JS, YASUI K, KODAMA I, SANGUINETTI MC: Open channel block of HERG K(+) channels by vesnarinone. Mol. Pharmacol. (2001) 60(2):244-253.
  • LEES-MILLER JP, DUAN Y, TENG GQ, DUFF HJ: Molecular determinant of high-affinity dofetilide binding to HERG1 expressed in Xenopus oocytes: involvement of S6 sites. Mol. Pharmacol. (2000) 57(2):367-374.
  • PERRY M, DE GROOT MJ, HELLIWELL R etal.: Structural determinants of HERG channel block by clofilium and ibutilide. Mol. Pharmacol. (2004) 66(2):240-249.
  • FERNANDEZ D, GHANTA A, KAUFFMAN GW, SANGUINETTI MC: Physicochemical features of the HERG channel drug binding site. J. Biol. Chem. (2004) 279(11):10120-10127.
  • SANCHEZ-CHAPULA JA, NAVARRO-POLANCO RA, CULBERSON C, CHEN J, SANGUINETTI MC: Molecular determinants of voltage-dependent human ether-a-go-go related gene (HERG) K+ channel block. J. Biol. Chem. (2002) 277(26):23587-23595.
  • SANCHEZ-CHAPULA JA, FERRER T, NAVARRO-POLANCO RA, SANGUINETTI MC: Voltage-dependent profile of human ether-a-go-go-related gene channel block is influenced by a single residue in the S6 transmembrane domain. Mol. Pharmacol. (2003) 63(5):1051-1058.
  • WITCHEL HJ, DEMPSEY CE, SESSIONS RB etal.: The low-potency, voltage-dependent HERG blocker propafenone-molecular determinants and drug trapping. Mol. Pharmacol. (2004) 66(5):1201-1212.
  • MITCHESON JS, PERRY MD: Molecular determinants of high-affinity drug binding to HERG channels. Curr. Opin. Drug Discov. Devel. (2003) 6(5):667-674.
  • MILNES JT, CROCIANI O, ARCANGELI A, HANCOX JC, WITCHEL HJ: Blockade of HERG potassium currents by fluvoxamine: incomplete attenuation by S6 mutations at F656 or Y652. Br. J. Pharmacol. (2003) 139(5):887-898.
  • MITCHESON JS: Drug binding to HERG channels: evidence for a non-aromatic binding site for fluvoxamine. Br. J. Pharmacol. (2003) 139(5):883-884.
  • SHEALY RT, MURPHY AD, RAMARATHNAM R, JAKOBSSON E, SUBRAMANIAM S: Sequence-function analysis of the K+-selective family of ion channels using a comprehensive alignment and the KcsA channel structure. Biophys. J. (2003) 84(5):2929-2942.
  • KUO A, GULBIS JM, ANTCLIFF JF etal.: Crystal structure of the potassium channel KirBac1.1 in the closed state. Science (2003) 300(5627):1922-1926.
  • ZHOU M, MACKINNON R: A mutant KcsA K(+) channel with altered conduction properties and selectivity filter ion distribution. J. Mol. Biol. (2004) 338(4):839-846.
  • PERRY M, STANSFELD PJ, LEANEY J etal.: Drug binding interactions in the inner cavity of hERG: Molecular insights from structure-activity relationships of clofilium and ibutilide analogues. Mol. Pharmacol. (2005) (In Press).
  • FICKER E, JAROLIMEK W, KIEHN J, BAUMANN A, BROWN AM: Molecular determinants of dofetilide block of HERG K+ channels. Circ. Res. (1998) 82(3):386-395.
  • SMITH PL, BAUKROWITZ T, YELLENG: The inward rectification mechanism of the HERG cardiac potassium channel. Nature (1996) 379(6568):833-836.
  • TSENG GN, GUY HR: Structurefunction studies of the outer mouth and voltage sensor domain of hERG. Novartis Found. Symp. (2005) 266:19-35; discussion 35-45.
  • HERZBERG IM, TRUDEAU MC, ROBERTSON GA: Transfer of rapid inactivation and sensitivity to the class III antiarrhythmic drug E-4031 from HERG to M-eag channels. J. Physiol. (1998) 511(Pt1):3-14.
  • FICKER E, JAROLIMEK W, BROWNAM: Molecular determinants of inactivation and dofetilide block in ether a-go-go (EAG) channels and EAG-related K(+) channels. Mol. Pharmacol. (2001) 60(6):1343-1348.
  • CHEN J, SEEBOHM G, SANGUINETTIMC: Position of aromatic residues in the S6 domain, not inactivation, dictates cisapride sensitivity of HERG and eag potassium channels. Proc. Natl. Acad. Sci.USA (2002) 99(19):12461-12466.
  • HEGINBOTHAM L, MACKINNON R: The aromatic binding site for tetraethylammonium ion on potassium channels. Neuron (1992) 8(3):483-491.
  • KOROLKOVA YV, TSENG GN, GRISHIN EV: Unique interaction of scorpion toxins with the hERG channel. J. Mol. Recognit. (2004) 17(3):209-217.
  • VOLBERG WA, KOCI BJ, SU W, LIN J, ZHOU J: Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics. J. Pharmacol. Exp. Ther. (2002) 302(1):320-327.
  • AKIMOTO K, FURUTANI M, IMAMURA S etal.: Novel missense mutation (G601S) of HERG in a Japanese long QT syndrome family. Hum. Mutat. (1998) (Suppl. 1):S184-S186.
  • FURUTANI M, TRUDEAU MC, HAGIWARA N etal.: Novel mechanism associated with an inherited cardiac arrhythmia: defective protein trafficking by the mutant HERG (G601S) potassium channel. Circulation (1999) 99(17):2290-2294.
  • DELISLE BP, ANSON BD, RAJAMANI S, JANUARY CT: Biology of cardiac arrhythmias: ion channel protein trafficking. Circ. Res. (2004) 94(11):1418-1428.
  • ZHOU Z, GONG Q, JANUARY CT: Correction of defective protein trafficking of a mutant HERG potassium channel in human long QT syndrome. Pharmacological and temperature effects. J. Biol. Chem. (1999) 274(44):31123-31126.
  • FICKER E, OBEJERO-PAZ CA, ZHAO S, BROWN AM: The binding site for channel blockers that rescue misprocessed human long QT syndrome type 2 ether-a-go-go-related gene (HERG) mutations. J. Biol. Chem. (2002) 277(7):4989-4998.
  • FICKER E, DENNIS A, KURYSHEV Y, WIBLE BA, BROWN AM: HERG channel trafficking. Novartis Found. Symp. (2005) 266:57-69; discussion 70-54, 95-59.
  • FICKER E, KURYSHEV YA, DENNIS AT etal.: Mechanisms of arsenic-induced prolongation of cardiac repolarization. Mol. Pharmacol. (2004) 66(1):33-44.
  • KURYSHEV YA, FICKER E, WANG L etal.: Pentamidine-induced long QT syndrome and block of hERG trafficking. J. Pharmacol. Exp. Ther. (2005) 312(1):316-323.
  • ECKHARDT LL, RAJAMANI S, JANUARY CT: Protein trafficking abnormalities: a new mechanism in drug-induced long QT syndrome. Br. J. Pharmacol. (2005) 145(1):3-4.
  • CORDES JS, SUN Z, LLOYD DB etal.: Pentamidine reduces hERG expression to prolong the QT interval. Br. J. Pharmacol. (2005) 145(1):15-23.
  • BROWN AM: HERG block, QT liability and sudden cardiac death. Novartis Found. Symp. (2005) 266:118-131; discussion 131-115, 155-118.
  • WITCHEL HJ, MILNES JT, MITCHESON JS, HANCOX JC: Troubleshooting problems with invitro screening of drugs for QT interval prolongation using HERG K+ channels expressed in mammalian cell lines and Xenopus oocytes. J. Pharmacol. Toxicol. Methods (2002) 48(2):65-80.
  • CHIU PJ, MARCOE KF, BOUNDS SE etal.: Validation of a [3H]astemizole binding assay in HEK293 cells expressing HERG K+ channels. J. Pharmacol. Sci. (2004) 95(3):311-319.
  • CHENG CS, ALDERMAN D, KWASH J etal.: A high-throughput HERG potassium channel function assay: an old assay with a new look. Drug Dev. Ind. Pharm. (2002) 28(2):177-191.
  • WIBLE BA, HAWRYLUK P, FICKER E etal.: HERG-Lite(R): a novel comprehensive high-throughput screen for drug-induced hERG risk. J. Pharmacol. Toxicol. Methods (2005) 52(1):136-145.
  • SANGUINETTI MC, MITCHESON JS: Predicting drug-hERG channel interactions that cause acquired long QT syndrome. Trends Pharmacol. Sci. (2005) 26(3):119-124.
  • RECANATINI M, POLUZZI E, MASETTI M, CAVALLI A, DE PONTI F: QT prolongation through hERG K(+) channel blockade: current knowledge and strategies for the early prediction during drug development. Med. Res. Rev. (2005) 25(2):133-166.
  • PEARLSTEIN RA, VAZ RJ, KANG J etal.: Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches. Bioorg. Med. Chem. Lett. (2003) 13(10):1829-1835.
  • CAVALLI A, POLUZZI E, DE PONTI F, RECANATINI M: Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers. J. Med. Chem. (2002) 45(18):3844-3853.
  • EKINS S, CRUMB WJ, SARAZAN RD, WIKEL JH, WRIGHTON SA: Three-dimensional quantitative structureactivity relationship for inhibition of human ether-a-go-go-related gene potassium channel. J. Pharmacol. Exp. Ther. (2002) 301(2):427-434.
  • ARONOV AM, GOLDMAN BB: A model for identifying HERG K+ channel blockers. Bioorg. Med. Chem. (2004) 12(9):2307-2315.
  • OSTERBERG F, AQVIST J: Exploring blocker binding to a homology model of the open hERG K+ channel using docking and molecular dynamics methods. FEBS Lett. (2005) 579(13):2939-2944.
  • HANSSON T, MARELIUS J, AQVIST J: Ligand binding affinity prediction by linear interaction energy methods. J. Comput. Aided Mol. Des. (1998) 12(1):27-35.
  • CRUMB WJ, JR.: Loratadine blockade of K(+) channels in human heart: comparison with terfenadine under physiological conditions. J. Pharmacol. Exp. Ther. (2000) 292(1):261-264.
  • TAGLIALATELA M, CASTALDO P, PANNACCIONE A etal.: Cardiac ion channels and antihistamines: possible mechanisms of cardiotoxicity. Clin. Exp. Allergy (1999) 29(Suppl. 3):182-189.
  • RAJAMANI S, ANDERSON CL, ANSONBD, JANUARY CT: Pharmacological rescue of human K(+) channel long-QT2 mutations: human ether-a-go-go-related gene rescue without block. Circulation (2002) 105(24):2830-2835.
  • TAGLIALATELA M, PANNACCIONE A, CASTALDO P etal.: Molecular basis for the lack of HERG K+ channel block-related cardiotoxicity by the H1 receptor blocker cetirizine compared with other second-generation antihistamines. Mol. Pharmacol. (1998) 54(1):113-121.
  • KIRSCH GE, TREPAKOVA ES, BRIMECOMBE JC etal.: Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern. J. Pharmacol. Toxicol. Methods (2004) 50(2):93-101.
  • LINDQUIST M, EDWARDS IR: Risks of non-sedating antihistamines. Lancet (1997) 349(9061):1322.
  • REDFERN WS, CARLSSON L, DAVISAS etal.: Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc. Res. (2003) 58(1):32-45.
  • RODEN DM: Taking the idio out of idiosyncratic: predicting torsades de pointes. Pacing Clin. Electrophysiol. (1998) 21(5):1029-1034.
  • RODEN DM, YANG T: Protecting the heart against arrhythmias: potassium current physiology and repolarization reserve. Circulation (2005) 112(10):1376-1378.
  • RAJAMANI R, TOUNGE BA, LI J, REYNOLDS CH: A two-state homology model of the hERG K+ channel: application to ligand binding. Bioorg. Med. Chem. Lett. (2005) 15(6):1737-1741.
  • LONG SB, CAMPBELL EB, MACKINNON R: Voltage sensor of Kv1.2: structural basis of electromechanical coupling. Science (2005) 309(5736):903-908.
  • JIANG Y, RUTA V, CHEN J, LEE A, MACKINNON R: The principle of gating charge movement in a voltage-dependent K+ channel. Nature (2003) 423(6935):42-48.
  • JOHNSON JP, JR., ZAGOTTA WN: The carboxyl-terminal region of cyclic nucleotide-modulated channels is a gating ring, not a permeation path. Proc. Natl. Acad. Sci. USA (2005) 102(8):2742-2747.
  • DUMAINE R, ROY ML, BROWN AM: Blockade of HERG and Kv1.5 by ketoconazole. J. Pharmacol. Exp. Ther. (1998) 286(2):727-735.
  • AMENT PW, PATERSON A: Drug interactions with the nonsedating antihistamines. Am. Fam. Physician (1997) 56(1):223-231.
  • RIDLEY JM, MILNES JT, WITCHEL HJ, HANCOX JC: High affinity HERG K(+) channel blockade by the antiarrhythmic agent dronedarone: resistance to mutations of the S6 residues Y652 and F656. Biochem. Biophys. Res. Commun. (2004) 325(3):883-891.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.